Lantern Pharma Inc. (LTRN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$47.2M
Cash & Equivalents
$3.8M
Quarterly Burn Rate
38 mo
Est. Cash Runway
$46M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-07-28 | Phase2 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | PHASE2 | Active Not Recruiting | 64 |
| NCT05456256 | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | PHASE2 | Recruiting | 90 |
| NCT06132503 | Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and So... | PHASE1 | Recruiting | 110 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.